Safety of midodrine in patients with heart failure with reduced ejection fraction: a retrospective cohort study. [PDF]
Front PharmacolBackground: Heart failure with reduced ejection fraction (HFrEF) poses significant health risks. Midodrine for maintaining blood pressure in HFrEF, requires further safety investigation.
Wu MJ, Chen CH, Tsai SF.
europepmc +3 more sources
Hemodynamic Effects of an Increased Midodrine Dosing Frequency
Critical Care Explorations, 2021 Objectives:. In practice, midodrine has been used to reduce IV vasopressor requirements and decrease ICU length of stay. However, recent publications have failed to show clinical success when midodrine was administered every 8 hours.
Shea A. Macielak, PharmD +4 more
doaj +4 more sources
Cardiology and Therapy, 2023 Background Studies evaluating the role of midodrine as an adjunctive therapy to liberate patients with shock from intravenous (IV) vasopressors have yielded mixed results.
Mohamed Hamed +9 more
doaj +2 more sources
Role of Midodrine on Vasopressor Duration in Patients with Sepsis [PDF]
Journal of Shock and Hemodynamics, 2023 Existing literature evaluating the off-label use of midodrine has focused primarily on postoperative hypotensive patients requiring a single vasopressor.
Belfer, Julie J +3 more
core +3 more sources
Use of midodrine in heart failure: a review
Annals of Medicine & Surgery, 2023 Heart failure is a global health concern, affecting millions of individuals worldwide. Midodrine, an alpha-1 receptor agonist, might be a potential treatment option for patients with heart failure and concurrent hypotension. This review provides a comprehensive summary of the existing literature on the use of midodrine in heart failure patients ...
Gautam, Sudarshan +8 more
openaire +3 more sources
Impact of Midodrine on Optimization of β-blocker Therapy in Patients with Heart Failure with Reduced Ejection Fraction [PDF]
Nursing & Health Sciences Research Journal, 2023 Introduction: Midodrine, an α-adrenergic agonist approved for orthostatic hypotension, is used off-label for hypotension in patients with heart failure with reduced ejection fraction (HFrEF). However, its prevalence, clinical outcomes, and risks in HFrEF
de Almeida, Kristen +4 more
core +3 more sources
Acute midodrine overdose: a case report [PDF]
Toxicology Communications, 2021 Midodrine is a prodrug metabolized to the peripheral acting alpha agonist desglymidodrine and is used to treat orthostatic hypotension. Reports of overdose are rare, consequently there is little guidance regarding treatment of overdose.
Jessica Peck, Steven D. Salhanick
doaj +3 more sources
Oral medications for the treatment of postural orthostatic tachycardia syndrome; a systematic review of studies before and during the COVID-19 pandemic. [PDF]
Front NeurolBackgroundPostural Orthostatic Tachycardia Syndrome (POTS) is a complex form of dysautonomia that presents with abnormal autonomic reflexes upon standing, leading to symptoms such as lightheadedness, tachycardia, fatigue, and cognitive impairment.
Pierson BC +7 more
europepmc +2 more sources
Utility of an Alpha-1 Adrenergic Agonist in the Management of Chylothorax: A Case Series and Management Algorithm. [PDF]
Eur J Case Rep Intern MedChylothorax is the accumulation of lymphatic fluid (chyle) within the pleural space. There are multiple causes, including traumatic and non-traumatic mechanisms.
Peralta R +5 more
europepmc +2 more sources
Management of hepatorenal syndrome and associated outcomes: a systematic reviews. [PDF]
BMJ Open GastroenterolBackground Hepatorenal syndrome (HRS), a multiorgan condition of acute kidney injury, is seen in advanced liver disease. This study aims to evaluate the current treatment for HRS.Methods The authors searched PubMed, Scopus and Google Scholar literature ...
Roozbeh J +4 more
europepmc +2 more sources